Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

Blood

Volumn 120, Issue 9, 2012, Pages 1765-1773

  Ranganathan, Parvathi ^a   Yu, Xueyan ^a   Na, Caroline ^a   Santhanam, Ramasamy ^a   Shacham, Sharon ^b   Kauffman, Michael ^b   Walker, Alison ^a   Klisovic, Rebecca ^a   Blum, William ^a   Caligiuri, Michael ^a   Croce, Carlo M ^a   Marcucci, Guido ^a   Garzon, Ramiro ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Karyopharm Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CD135 ANTIGEN; KPT 185; KPT 276; NUCLEOPHOSMIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLAST CELL; CANCER SURVIVAL; CELL CYCLE ARREST; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TUMOR XENOGRAFT; WILD TYPE;

EID: 84865749132     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-423160     Document Type: Article

References (50)

1. Bednenko J, Cingolani G, Gerace L. Nucleocytoplasmic transport: navigating the channel. Traffic. 2003;4(3):127-135.
2. Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol. 2007;17(4):193-201.
3. Turner JG, Sullivan DM. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem. 2008;15(26):2648-2655.
4. Fukuda M, Asano S, Nakamura T, et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature. 1997;390(6657):308-311.
5. Ossareh-Nazari B, Bachelerie F, Dargemont C. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science. 1997;278(5335):141-144.
6. Kanai M, Hanashiro K, Kim SH, et al. Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat Cell Biol. 2007;9(10):1175-1183.
7. Connor MK, Kotchetkov R, Cariou S, et al. CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell. 2003;14(1):201-213.
8. Shinmura K, Tarapore P, Tokuyama Y, George KR, Fukasawa K. Characterization of centrosomal association of nucleophosmin/B23 linked to Crm1 activity. FEBS Lett. 2005;579(29):6621-6634.
9. Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol. 2005;7(8):823-830.
10. Mutka SC, Yang WQ, Dong SD, et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 2009;69(2):510-517.
11. Stommel JM, Marchenko ND, Jimenez GS, et al. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 1999;18(6):1660-1672.
12. Vousden KH, Woude GF. The ins and outs of p53. Nat Cell Biol. 2000;2(10):E178-E180.
13. Noske A, Weichert W, Niesporek S, et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 2008;112(8):1733-1743.
14. Shen A, Wang Y, Zhao Y, et al. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery. 2009;65(1):153-159, discussion 159-160.
15. van der Watt PJ, Maske CP, Hendricks DT, et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer. 2009;124(8):1829-1840.
16. Keeshan K, Cotter TG, McKenna SL. Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway. Br J Haematol. 2003;123(1):34-44.
17. Zhou BP, Liao Y, Xia W, et al. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001;3(3):245-252.
18. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer. 1996;74(4):648-649.
19. G. F. Draetta, S. Shacham, M. Kauffman, et al. Cytotoxicity of novel, small molecule, CRM1-selective inhibitors of nuclear export (SINE) in colorectal cancer (CRC) cells [abstract]. J Clin Oncol. 2011;29: Abstract e14091.
20. Shacham S, Joel G Turner P, Nir R, et al. Preclinical development of small-molecule CRM1 inhibitors as novel therapy for the treatment of myeloma and other hematological malignancies [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116: Abstract 3012.
21. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012;83(8):1021-1032.
22. Azmi AS, Kauffman M, McCauley D, Shacham S, Mohammad RM. Novel small-molecule CRM-1 inhibitor for GI cancer therapy [abstract]. J Clin Oncol. 2012;30(Suppl 4): Abstract 245.
23. McCauley D, Landesman Y, Senapedis W, et al. Preclinical evaluation of selective inhibitors of nuclear export (SINE) in basal-like breast cancer (BLBC) [abstract]. J Clin Oncol. 2012;30(Suppl):Abstract 1055.
24. Walker C, Oaks JJ, Santhanam R, et al. Nuclear export (karyopherin) inhibitors: a novel therapeutic strategy for treating Philadelphia-positive (Ph+) acute leukemias. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, March 31 to April 4, 2012, Chicago, IL: Abstract 3839.
25. Lapalombella R, Berglund C, Mahoney E, et al. CRM1/XPO1 represents a promising therapeutic target for treatment of chronic lymphocytic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;116: Abstract 232.
26. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894- 1907.
27. Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109(2):431-448.
28. Falini B, Bolli N, Shan J, et al. Both carboxyterminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006;107(11):4514-4523.
29. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2007;109(3):874-885.
30. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006;6(7):493-505.
31. Li Z, Hann SR. The Myc-nucleophosmin-ARF network: a complex web unveiled. Cell Cycle. 2009;8(17):2703-2707.
32. Meani N, Alcalay M. Role of nucleophosmin in acute myeloid leukemia. Expert Rev Anticancer Ther. 2009;9(9):1283-1294.
33. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254-266.
34. Falini B, Sportoletti P, Martelli MP. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol. 2009;21(6):573-581.
35. Cheng K, Sportoletti P, Ito K, et al. The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. Blood. 2010;115(16):3341-3345.
36. Sakakibara K, Saito N, Sato T, et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011;118(14):3922-3931.
37. Quentmeier H, Martelli MP, Dirks WG, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia. 2005;19(10):1760-1767.
38. Ikeda H, Kanakura Y, Tamaki T, et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 1991;78(11):2962-2968.
39. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24(24):3904-3911.
40. Lekstrom-Himes J, Xanthopoulos KG. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem. 1998;273(44):28545-28548.
41. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90(2):489-519.
42. Pabst T, Mueller BU, Harakawa N, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med. 2001;7(4):444-451.
43. Keeshan K, Santilli G, Corradini F, Perrotti D, Calabretta B. Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation. Blood. 2003;102(4):1267-1275.
44. Yoon K, Smart RC. C/EBPalpha is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes. Mol Cell Biol. 2004;24(24):10650-10660.
45. Meyer M, Rubsamen D, Slany R, et al. Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS One. 2009;4(11):e7768.
46. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol. 2002;4(7):529-533.
47. Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009;23(10):1731-1743.
48. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer. 2003;3(2):89-101.
49. Bruserud O, Gjertsen BT. New strategies for the treatment of acute myelogenous leukemia. Differentiation induction: present use and future possibilities. Stem Cells. 2000;18(3):157-165.
50. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59-66.